UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 1, 2007
SYNVISTA
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-16043
|
|
13-3304550
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
No.)
|
221
West Grand Avenue
Montvale,
New Jersey 07645
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: (201) 934-5000
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see
General
Instruction A.2. below):
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
ITEM
8.01 OTHER EVENTS
On
October 1, 2007, Synvista Therapeutics, Inc., a Delaware corporation (the
“Company”), announced that Dr. Carl Mendel, MD, has joined the Company as its
Vice President of Clinical Development and Chief Medical Officer, commencing
on
October 1, 2007. Dr. Mendel will receive an annual salary of $265,000 and will
be eligible to receive an annual cash bonus based on predetermined milestones
of
up to 20% of his annual salary. In addition, upon commencement of his employment
with the Company, Dr. Mendel will be granted options to purchase 70,000 shares
of the Company’s common stock at an exercise price equal to the closing price of
the common stock on the grant date. Dr. Mendel will be an at-will employee
of
the Company.
A
copy of
the press release announcing Dr. Mendel’s appointment is attached hereto as
Exhibit 99.1 and incorporated herein by reference.
ITEM
9.01 FINANCIAL STATEMENTS AND EXHIBITS
99.1 |
Press Release dated October 1, 2007.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
|
SYNVISTA THERAPEUTICS,
INC. |
|
|
|
Dated:
October 1, 2007 |
By: |
/s/ Noah
Berkowitz, M.D., Ph.D. |
|
Noah
Berkowitz, M.D., Ph.D. |
|
President
and
Chief Executive Officer |
EXHIBIT
INDEX
Exhibit
Number |
Description |
99.1 |
Press Release dated October 1, 2007.
|